Generics Pharma
Global Market
Oral administration segment is estimated to grow at this remarkable rate and account for the largest share of the market.
Projected to surpass ~$575 Billion by 2027
-
Total generic market growth projected to grow at a 5.6% CAGR up to 2027
-
North America dominated the generic drugs market and is projected to retain its trend
Webinar + Presentation with Laxxon CEO Helmut Kerschbaumer – November 14, 2024
Laxxon CEO Helmut Kerschbaumer shares exclusive company updates in latest webinar from November 14, 2024.
December 20, 2023 Shareholder Update Meeting Presentation
Review the Shareholder Update Meeting Presentation from December, 20 2023
22nd Annual Needham Virtual Healthcare Conference
Our CEO Helmut Kerschbaumer is speaking at the 22nd Annual Needham Virtual Healthcare Conference.
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent 11,419,824 B2 for the controlled administration of one or more active pharmaceutical ingredients within a drug delivery system via oral dosage forms.
Development of Laxxon's Levodopa Project
Our CSO Achim Schneeberger discusses progress on the Levodopa project where our technology helps us improve the quality of life for patients.
Investor News & Updates
Frequently Asked Questions
What is Laxxon Medical, and when was it founded?
Laxxon Medical was founded in 2017 in Switzerland by Helmut Kerschbaumer, Klaus Kuehne, and Achim Schneeberger. The company, currently headquartered in New York, is transforming pharmaceutical development through its innovative SPID®-Technology (Screen Printing of Individualized Dosage forms). Our advanced additive manufacturing platform allows for the creation of next-generation oral dosage forms that provide compartmentalization and precise control over the release of active pharmaceutical ingredients (APIs). This enables features such as sequential drug release, multi-compartment microtablets, and targeted drug delivery.
What is Laxxon's core technology platform?
Our proprietary SPID®-Technology delivers precise pharmaceutical manufacturing for solid oral dosage forms (and beyond). The platform creates novel drug release profiles, including delayed, pulsatile, and multi-phase release with superior control over traditional methods from small batch sizes for R&D purposes, with direct upscaling to mass production.
What is Laxxon’s business model?
We are a privately held drug development expertise company with three core solutions: co-development partnerships, leveraging advanced generics pipeline through drug repurposing, and patent extension services. We specialize in the 505(b)(2) regulatory pathway for efficient development.
Does Laxxon Medical provide regular financial updates to stakeholders and investors?
Laxxon Medical provides a semi-annual financial summary, along with information on company achievements, milestones, and strategic partnerships to stakeholders and investors.
What makes Laxxon's intellectual property portfolio strong?
We maintain an extensive global patent portfolio that provides strong competitive protection. Together with our partner Exentis, we control > 230 patents and patent applications, protecting the technology as such but also product-related functionalities. Patent protection for repurposed drugs extends into the 2040s, delivering significant commercial advantages.
What therapeutic areas does Laxxon focus on?
Our platform is optimized for solid oral dosage forms and controlled release formulations. We focus on specialty pharmaceuticals and drug repurposing, where precision printing delivers clinical and commercial benefits. This holds particular significance for therapeutic areas including central nervous system and cardiovascular disease. It also enables oral applications of molecules that are known to be applied via injection, such as peptides.
How does Laxxon handle manufacturing?
We are partnering with an established Contract Development and Manufacturing Organization (CDMO) for scalable, Good Manufacturing Practice (GMP)-compliant production. This allows us to focus on innovation and development while leveraging proven manufacturing capabilities. If an industrial partner intends to do the SPID manufacturing itself e.g., after successful product development services provided by Laxxon, pending on corresponding license agreements, this can be an option as well.
What is Laxxon's position in the pharmaceutical market?
We are a leader in pharmaceutical printing technology with a strategic partnership-driven growth model focused on specialty and generic drug markets.
Strategic Commercialization
Laxxon offers three disruptive avenues for strategic opportunities within the pharmaceutical industry:
Invest in Laxxon
Strategic Partnerships
Branded generics dominated the market in 2020, but pure generics are anticipated to surpass branded generics by 2027.
Advanced Patented Generics
Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects. Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.
Patent Extension
Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to "extend" their patents through Technology Transfer. Our additive approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP. Our "Patent Extension" through Technology Transfer solution is for registered and safe pharmaceutical drugs on the market.
New Drug Development
Laxxon serves as a one-stop research, development, engineering, and manufacturing shop for pharmaceutical companies seeking new drug development. SPID®-Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production with no change to the manufacturing process. Laxxon offers price-aggressive manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development.
